The efficacy, safety, and the predictive factors of efficacy of low dose Lenalidomide plus Dexamethasone consolidation therapy followed by very low dose Lenalidomide maintenance therapy for multiple myeloma.

The efficacy, safety, and the predictive factors of efficacy of low dose Lenalidomide plus Dexamethasone consolidation therapy followed by very low dose Lenalidomide maintenance therapy for multiple myeloma. - The efficacy, safety, and the predictive factors of efficacy of rd therapy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007785

Enrollment

Registered

2012-04-19

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

treatment of Lenalidomide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to the International Myeloma Working Group (IMWG) criteria, patients younger than 75 years with symptomatic MM were eligible for this trial.

Exclusion criteria

Exclusion criteria: The exclusion criteria were a serum creatinine level>2.05 mg/dL, liver dysfunction (e.g., a serum total bilirubin level>2.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (>grade 3), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer.

Design outcomes

Primary

Measure	Time frame
complete response rate	—

Secondary

Measure	Time frame
1)CTL Ratio in the peripheral blood 2)Blood concentration of lenalidomide 3)Cytokine concentration 4)Chemokine concentration 5)Safety	—

Countries

Japan

Contacts

Public ContactNaoki Takaezako

National Hospital Organization Disaster Medical Center Hematology

ntakezak@tdmc.hosp.go.jp+81-42-526-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026